Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 December 2017Website:
http://www.cohbar.comNext earnings report:
19 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 81 min agoDividend
Analysts recommendations
Institutional Ownership
CWBR Latest News
CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.
What type of business is CohBar?
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
What sector is CohBar in?
CohBar is in the Healthcare sector
What industry is CohBar in?
CohBar is in the Biotechnology industry
What country is CohBar from?
CohBar is headquartered in United States
When did CohBar go public?
CohBar initial public offering (IPO) was on 15 December 2017
What is CohBar website?
https://www.cohbar.com
Is CohBar in the S&P 500?
No, CohBar is not included in the S&P 500 index
Is CohBar in the NASDAQ 100?
No, CohBar is not included in the NASDAQ 100 index
Is CohBar in the Dow Jones?
No, CohBar is not included in the Dow Jones index
When was CohBar the previous earnings report?
No data
When does CohBar earnings report?
The next expected earnings date for CohBar is 19 November 2024